Background: Epithelial barrier dysfunction and increased permeability may contribute to antigen sensitization and disease progression in asthma. Claudin-18.1 is the only known lungspecific tight junction protein, but its contribution to airway barrier function or asthma is unclear. Objectives: We sought to test the hypotheses that claudin-18 is a determinant of airway epithelial barrier function that is downregulated by IL-13 and that claudin-18 deficiency results in increased aeroantigen sensitization and airway hyperresponsiveness. Methods: Claudin-18.1 mRNA levels were measured in airway epithelial brushings from healthy controls and patients with asthma. In patients with asthma, claudin-18 levels were compared with a three-gene-mean marker of T H 2 inflammation. Airway epithelial permeability changes due to claudin-18 deficiency were measured in 16HBE cells and claudin-18 null mice. The effect of IL-13 on claudin expression was determined in primary human airway epithelial cells and in mice. Airway hyperresponsiveness and serum IgE levels were compared in claudin-18 null and wild-type mice following aspergillus sensitization. Results: Epithelial brushings from patients with asthma (n 5 67) had significantly lower claudin-18 mRNA levels than did those from healthy controls (n 5 42). Claudin-18 levels were lowest among T H 2-high patients with asthma. Loss of claudin-18 was sufficient to impair epithelial barrier function in 16HBE cells and in mouse airways. IL-13 decreased claudin-18 expression in primary human cells and in mice. Claudin-18 null mice had significantly higher serum IgE levels and increased airway responsiveness following intranasal aspergillus sensitization. Conclusions: These data support the hypothesis that claudin-18 is an essential contributor to the airway epithelial barrier to aeroantigens. Furthermore, T H 2 inflammation suppresses claudin-18 expression, potentially promoting sensitization and airway hyperresponsiveness. (J Allergy Clin Immunol 2017;139:72-81.) 
Genetic and environmental factors influence asthma development, progression, and severity. Moreover, recent work has begun to parse the clinical syndrome of asthma into distinct endotypes that may vary in pathogenesis, progression, and response to therapy. 1 Amid this complexity, airway epithelial barrier impairment is a common feature of asthma that has been postulated to contribute to immune and parenchymal cell activation, antigen sensitization, and airway hyperresponsiveness. 2, 3 In severe asthma, epithelial cell loss has been reported, but previous work has also demonstrated that more subtle changes in epithelial cell junctions may account for impaired barrier function in mild-moderate asthma. 4 For example, infections, toxins, and environmental proteins, such as Dpr1, modify cell junctions to impair barrier function. [5] [6] [7] Moreover, recent work also supports the hypothesis that differences in tight junction protein expression or trafficking account for differences in barrier function in the epithelium of those with asthma. For example, biopsy samples from subjects with asthma exhibit tight junction disruption with reduced expression of occludin and zona occludens-1-key structural components of tight junctions. 8 In parallel, cultured epithelial monolayers derived from airways of subjects with asthma had increased macromolecule permeability compared with monolayers derived from healthy subjects. 8 Because the airway epithelium constitutes a barrier to aeroantigens, these findings raise the possibility that increased epithelial permeability could contribute to allergic inflammation by permitting greater exposure of the subepithelial compartment to inhaled allergens. Alternatively, loss of epithelial compartmentalization and polarity could impact cell signaling through dysregulation of normally segregated receptors and ligands. The mechanisms of airway epithelial tight junction dysfunction in asthma, and the contribution of this abnormality to allergic sensitization and airway hyperresponsiveness, remain incompletely understood.
It is noteworthy that previous studies have established that T H 2-mediated changes in tight junction claudin expression contribute to impaired epithelial barrier function in the gut and Abbreviations used GAPDH: Glyceraldehyde 3-phosphate dehydrogenase OVA: Ovalbumin P app : Apparent permeability PAS: Periodic acid-Schiff UCSF: University of California, San Francisco other organs. [9] [10] [11] It is less clear whether this mechanism contributes to airway epithelial barrier abnormalities in asthma; however, a previous report found that IL-4 and IL-13 impaired epithelial barrier function in 16HBE cells. 12 T H 2-high asthma is characterized by higher expression levels of IL-13-dependent genes, greater airway hyperresponsiveness, and higher IgE levels compared with T H 2-low asthma. 13, 14 It remains unclear whether tight junction composition and epithelial barrier function differ among subjects with T H 2-high and T H 2-low asthma.
Claudins are essential to tight junction formation and are a primary determinant of paracellular permeability through intact tight junctions. Differential claudin expression accounts for the differences in epithelial permeability in diverse epithelia, and mutations in claudin genes and changes in claudin expression result in clinical disease. 15, 16 The claudin-18 gene encodes 2 variants that differ in the first exon. Claudin-18.1 expression requires the transcription factor NKX2-1 and is exclusive to lung epithelia. 17 At present, claudin-18.1 is the only known lung-specific tight junction gene product. The expression of specific claudin family members may vary in different airway epithelial cell types, but claudins-1, -4, and -7 are expressed at high levels in airway epithelium. 18, 19 Although claudin-18 is also normally expressed in airway epithelial cells, its contribution to the permeability barrier in the airways has not been fully defined.
This study was undertaken to determine the contribution of claudin-18 to airway epithelial barrier function and whether claudin-18 expression is regulated by T H 2 inflammation. In addition, the consequences of claudin-18 deficiency to aeroantigen sensitization and airway hyperresponsiveness were examined. The presented data substantiate the hypothesis that claudin-18 is a central barrier-forming component of tight junctions and show that IL-13 downregulates claudin-18. These data also suggest that the loss of claudin-18 is associated with increased sensitization to aeroantigens and airway responsiveness.
METHODS

Airway mRNA expression studies
Aliquots of RNA extracted from airway epithelial brushings and stored in the Airway Tissue Bank at the University of California, San Francisco (UCSF) were analyzed by quantitative PCR as previously described. 20 The UCSF Committee on Human Research approved the policies and procedures of the UCSF Airway Tissue Bank and use of samples for this study. These epithelial brushings had been collected during research bronchoscopy from 67 nonsmoking subjects with asthma and 42 healthy nonsmoking control subjects (Table I ). All subjects signed an Airway Tissue Bank informed consent form approved by the UCSF Committee on Human Research. Subjects with asthma had a prior physician's diagnosis of asthma, a PC 20 methacholine value of less than 8 mg/mL, and were using only inhaled b-agonist medications for therapy. RNA was reverse transcribed with random hexamer primers and then amplified in a multiplex reaction with custom primers (see Table E1 in this article's Online Repository at www.jacionline.org). The amplified cDNA was then used for quantitative PCR with custom primers and Taqman-based probes run in separate batches. 13, 21 Normalization was done using the geometric mean of the value of 3 housekeeping genes as previously described. 21, 22 Log2 transformed, normalized, relative expression is reported. The three-gene-mean marker of T H 2 inflammation was determined as described previously. 13, 14 This measure is based on the geometric mean of mRNA expression levels of CLCA1, SERPINB2, and POSTN. Claudin-18 mRNA expression levels were compared with serum IgE levels and blood eosinophil counts obtained from subjects with asthma at the time of bronchoscopy.
Primary cell culture and immunostaining
Cadaveric airway tissues from lungs rejected for transplantation were obtained in accordance with UCSF Committee on Human Research approval from the Northern California Organ Donor Network. Normal airway surface epithelial cells were harvested from 8 individual donors and expanded and cultured at an air-liquid interface as described previously. 23, 24 Treatment with IL-13 (10 ng/mL) was begun at 2 weeks, once air-liquid interface cultures had established confluence, and continued for 7 days. Recombinant human IL-13 (R&D Systems, Minneapolis, Minn) was reconstituted in sterile PBS containing 0.1% BSA. For primary human airway epithelial cells, quantitative PCR was done without preamplification. Normalization was done as above using EEF1A1 and PPIA. Data are reported as relative mRNA expression normalized to the housekeeping genes. Claudin-18 protein levels were compared in cell lysates using immunoblot densitometry normalized to tubulin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Blots were incubated with claudin-18 and tubulin primary antibodies in series and images developed such that both bands could be visualized on the same blot. In addition, separate, equally loaded blots were probed for either claudin-18 or GAPDH. Data normalized to tubulin or GAPDH were similar and the GAPDH data are shown. For immunostaining, tissue was fixed in 4% paraformaldehyde and embedded in paraffin. Tissue sections were stained for beta catenin (G10, Santa Cruz Biotechnology, Santa Cruz, Calif) and claudin-18 (ZMD.385, Life Technologies, Waltham, Mass) and counterstained with 49-6-diamidino-2-phenylindole, dihydrochloride.
16HBE cell culture
16HBE cells (a gift from Dr Dieter Gruenert, UCSF) were cultured in minimum essential medium Eagle's with Earle's basic salt solution medium supplemented with 10% BSA, 1% penicillin/streptomycin, and 1% glutamine. A coating medium comprising LHC basal media, 0.1% type 1 collagen, 0.1% BSA, and 0.1% fibronectin was used to coat the culture plates. Cells were cultured until they reached 80% confluence, and 250,000 cells/cm 2 were then passaged on to 1.13-cm 2 Transwell polycarbonate inserts (3407, Corning Costar, Sigma Aldrich, St Louis, Mo) treated with coating medium. Claudin-18 and tubulin protein expression levels were measured using Western blotting, and densitometry data were analyzed using ImageJ (National Institutes of Health, Bethesda, Md). Data are reported as claudin-18/tubulin. Transepithelial electrical resistance was measured using a voltohm meter (World Precision Instruments, Sarasota, Fla). Permeability to the 500 Dalton fluorescent tracer pyranine was measured by adding 10 mg/mL pyranine to the apical chamber of transwells and measuring fluorescence recovery in the basolateral chamber. 25 Data are reported as apparent permeability (P app ).
shRNA studies
Claudin 18 shRNA sequences (TRCN0000116737 to TRCN 000011673741) were cloned into the third-generation lentiviral vector pLKO.1-puro (Sigma Mission shRNA library) and transfer plasmids were cotransfected with packaging plasmids and VSV-G-expressing envelope plasmid into human 293 cells at low passage and 30% confluence. When the cells became confluent (36-48 hours), the culture medium was collected and filtered. Supernatants were aliquoted and kept at 2808C. After confirmation of posttransduction knock down by immunoblot, J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1 transepithelial electrical resistance of stable monolayers and paracellular permeability to pyranine were measured as previously described. 25 
Mouse studies
Animal studies were done in accordance with local Institutional Animal Research Committee approval. Constitutive Cldn18 2/2 mice on the C57/b6
background were generated by the trans-NIH Knock-Out Mouse Project. The knock-out strategy targeted a 17-kB DNA genome segment encompassing the 5 exons of claudin-18.1. Isoflurane-anesthetized mice were exposed to aspergillus 100 mg antigen (Hollister, Spokane, Wash) in 40 mL saline or saline alone intranasally 3 times per week for 3 weeks as previously described.
26
One day after the final aspergillus administration, mice were anesthetized with ketamine/acepromazine (90/2 mg/kg) and received pancuronium (1 mg/kg). Airway resistance was measured with a FlexiVent system (Scireq, Montreal, Quebec, Canada) before and after increasing doses of acetylcholine (intravenous). Total serum IgE level was measured as previously described. 26 Separate claudin-18 null and wild-type mice were sensitized intraperitoneally with 20 mg of aspergillus mixed with 20 mg of aluminum potassium sulfate (alum) on days 0 and 14. Control animals received an equal volume of alum alone. Mice were euthanized for serum harvesting 3 days after the second sensitization. Additional mice were sensitized on days 0, 7, and 14 by intraperitoneal injection of 50 mg ovalbumin (OVA, Sigma Aldrich) emulsified in 1 mg alum. Control animals received an equal volume of alum alone. Mice were euthanized for serum harvesting 7 days after the third sensitization. OVAspecific IgE levels were measured by ELISA using microplates coated with OVA. Diluted serum samples were added to each well, and the bound IgE was detected with biotinylated antimouse IgE (R35-118; Pharmingen, Stamford, Conn).
To further explore the effect of IL-13 on claudin-18 expression in vivo, previously described IL-13-overexpressing transgenic mice and wild-type C57/b littermate controls were compared. 27, 28 Lung tissue was collected and mRNA and protein extracted. Claudin-18 mRNA and protein abundance was determined as described above.
Tracheal epithelial permeability to macromolecules was measured as previously described 29 with slight modification. Briefly, tracheas from claudin-18 null and wild-type littermates were cannulated at both ends with PE50 tubing and instilled with 50 mL Krebs buffer containing 1 mg/mL of the 0.5-kD fluorophore pyranine. Temperature was maintained at 378C for 30 minutes. Tracheas were then gently flushed with 300 mL tracer-free Krebs buffer and homogenized in 250 mL fresh buffer. Before homogenization, tracheal segment width and length, spanning the distance between the sutures securing the PE50 tubing, were recorded for determination of tracheal epithelial surface area. Homogenates were centrifuged for 10 minutes at 12,000g and fluorescence was measured in 100-mL aliquots of supernatant. Tracheal epithelial permeability is reported as P app or (dQ/dT)/CA, where dQ/dT is the permeation rate of tracer as a mass per time, C is the initial concentration of tracer in the buffer, and A is the tracheal epithelial surface area.
Histology
Lungs were inflated with 10% buffered formalin to a pressure of 25 cm H 2 O. Sections (5 mm) of the entire lung were stained with hematoxalin and eosin, periodic acid-Schiff (PAS), or Sirius red. PAS staining was scored in a semi-quantitative fashion as previously reported. 30 Airway fibrosis was quantified using the area/perimeter method as previously reported. 31 
Statistics
Comparisons between 2 groups were done by t test for normally distributed data or by the Wilcoxon rank-sum test. Claudin-18 mRNA expression in airway brush samples was compared using ANOVA with posttest for linear trend and post hoc Bonferroni correction for multiple comparisons. For airway resistance data, ANOVA and pairwise, post hoc Bonferroni correction was done. For primary cell culture studies, Friedman test with Dunn correction for multiple comparisons was used. P values of less than .05 were considered statistically significant. Statistics were calculated using Prism v6.04 (GraphPad Software, La Jolla, Calif). Data are shown as mean 6 SEM unless otherwise indicated.
RESULTS
Claudin-18 expression is decreased in asthma and is inversely associated with T H 2 inflammation
Claudin-18 mRNA levels were lower in epithelial brush samples from subjects with asthma (n 5 67) than from healthy controls (n 5 42) (Fig 1, A) . Claudin-18 levels were lower in subjects with asthma with low three-gene-mean values than in healthy controls and were lowest in subjects with asthma with higher three-gene-mean values (P < .0001 by ANOVA with a significant linear trend). T H 2-high subjects with asthma (n 5 44) had the lowest claudin-18 mRNA levels (P < .05 compared with healthy subjects following post hoc Bonferroni test for multiple comparisons). Consistent with previous reports, 13 most subjects with asthma were T H 2-high (44 of 67) as defined by a threegene-mean of greater than 0.1. Although protein samples were not available from the epithelial brush samples used in this study, the presence of claudin-18 protein was examined in airway epithelium from cadaveric tracheal tissue (Fig 1, B) . Claudin-18 immunolocalized to the epithelium as defined by the presence of beta catenin. Among subjects with asthma, there was a modest inverse correlation between serum IgE levels and claudin-18 levels in the airway brush samples (rs 5 20.31) (Fig 1, C) . There was also an inverse correlation between claudin-18 levels and blood eosinophil counts among subjects with asthma (rs 5 20.42) (Fig 1, D) .
IL-13 decreases claudin-18 mRNA and protein levels in primary human airway epithelial cells
In primary human airway epithelial cells, IL-13 induced a significant decrease in claudin-18 protein expression compared with vehicle-treated controls (Fig 2, A) . IL-13 significantly decreased claudin-18 mRNA levels, but did not significantly change mRNA levels of claudin-1, claudin-4, or claudin-7 (n 5 8 separate donors) (Fig 2, B) .
Loss of claudin-18 impairs epithelial barrier function
In 16HBE cells, claudin-18-targeted shRNA decreased claudin-18 protein levels by approximately 50% (Fig 3, A) , but did not significantly affect protein levels of claudin-1, claudin-4, or claudin-7. Claudin-1 protein expression in cldn18-targeted shRNA-treated cells was 110% 6 20% of control shRNAtreated cells. Claudin-4 protein expression was 91% 6 15% and claudin-7 protein expression was 114% 6 10% of control shRNA-treated cells based on densitometry normalized to tubulin (n 5 6 biologic replicates).
Knock down of claudin-18 resulted in a significant decrease in transepithelial electrical resistance and a significant increase in epithelial permeability to the 0.5-kD tracer pyranine in 16HBE cells (P < .05) (Fig 3, B and C) .
Tracheal epithelial permeability to pyranine was assessed in wild-type and claudin-18 null mice (n 5 6 in each group). This method yielded permeability values comparable to those in previous studies of airway permeability in wild-type mice (P app 5 3.3 6 0.3 3 10 27 cm/s). Consistent with the in vitro claudin-18 knock-down studies, tracheal epithelial permeability was more than 2-fold higher in claudin-18 null mice (P < .05) (Fig 4, D) .
Claudin-18 deficiency increased sensitization to aeroantigens and airway responsiveness in mice
To investigate the association between claudin-18, epithelial barrier function, and asthma, claudin-18 knock-out mice were FIG 3 . Claudin-18 is required for the airway epithelial permeability barrier. A, Claudin-18-shRNA decreased claudin-18 protein levels in 16HBE cells (*P < .05). Representative blot above with densitometry (n 5 6) below. Claudin-18 knock down decreased transepithelial electrical resistance (TER) (B) and increased P app (*P < .05) (C). D, Tracheal epithelial permeability in claudin-18 null and wild-type mice (n 5 6 in each group, *P < .01). KO, Knockout; WT, wild-type.
exposed to intranasal aspergillus antigen. Following the final intranasal exposure, serum IgE levels and airway resistance changes in response to intravenous acetylcholine were measured. Compared with wild-type mice, claudin-18 null mice showed increased airway responsiveness to acetylcholine following intranasal aspergillus sensitization (Fig 4, A) (P < .01). Control, saline-treated, claudin-18 knock-out mice were not different from saline-treated wild-type mice (n 5 6-8 in each group).
Serum IgE levels in intranasally sensitized cldn18 null mice were significantly higher than in aspergillus-treated wild-type mice and saline-treated control mice (Fig 4, B) . To determine whether the airway route of administration accounted for the difference in sensitization to aspergillus, additional mice were sensitized to aspergillus antigen using the intraperitoneal route. Serum IgE levels were not different in knock-out and wild-type mice given intraperitoneal aspergillus antigen (Fig 4, C) . To further evaluate for baseline differences in antigen sensitization, additional mice were sensitized to OVA via the intraperitoneal route and OVA-specific IgE levels were measured in serum. OVA-specific IgE levels were not different between knock-out and wild-type mice (Fig 4, C) .
On lung histology, there was no difference in airway mucin between genotypes at baseline as quantified by PAS staining. Intranasal aspergillus sensitization increased PAS staining to a similar degree in both genotypes (Fig 4, D) . Similarly, aspergillus sensitization increased airway collagen to a comparable degree in both genotypes. Although airway collagen was slightly higher in knock-out mice after aspergillus sensitization, the difference did not reach statistical significance (n 5 6-8 in each group) (Fig 4, E) .
IL-13 overexpression in vivo decreases claudin-18 mRNA and protein expression
To test whether IL-13 decreases lung claudin-18 expression in vivo, previously described transgenic IL-13-overexpressing mice were compared with wild-type littermates. Claudin-18 protein expression, normalized to tubulin, was significantly decreased in IL-13 transgenic mice compared with wild-type mice (Fig 5, A) . Using quantitative PCR, it was found that claudin-18 mRNA levels, normalized to beta actin, were also significantly decreased (Fig 5, B) . Claudin-4 mRNA expression was significantly increased in IL-13-overexpressing transgenic mice and claudin-1 and claudin-7 mRNA levels were not different between the genotypes (n 5 6 in each group) (Fig 5, B) .
DISCUSSION
The overall objective of this study was to establish the role of claudin-18 in airway epithelial barrier function and determine whether claudin-18 is regulated by mediators of T H 2 inflammation. Based on the hypothesis that claudin-18 is a requirement for the epithelial permeability barrier, the contribution of claudin-18 to aeroantigen sensitization and airway responsiveness was investigated with the prediction that serum IgE and airway responsiveness would be increased in the setting of claudin-18 deficiency. The primary findings of this study are that claudin-18 levels are decreased in subjects with asthma in association with T H 2 inflammation and that IL-13 acts to decrease claudin-18 expression in primary human cells and in mice. In addition, subjects with asthma with low claudin-18 mRNA levels had higher serum IgE levels and blood eosinophil counts. Claudin-18-deficient mice developed a greater increase in serum IgE following intranasal but not intraperitoneal aspergillus antigen sensitization. Claudin-18-deficient mice also developed greater airway hyperresponsiveness compared with wild-type mice following intranasal aspergillus sensitization. Together these data support the hypothesis that claudin-18 is a requirement for airway epithelial barrier function and suggest that increased epithelial permeability may contribute to greater antigen sensitization and airway responsiveness in asthma. Because T H 2 inflammation decreases claudin-18 expression, the data in this study are consistent with the hypothesis that T H 2 inflammation and epithelial barrier dysfunction can participate in a feed forward loop in asthma that includes the downregulation of claudin-18.
The contributors to disease development and severity in asthma are manifold; however, epithelial barrier dysfunction may represent a common physiological feature of asthma that is downstream to diverse genetic and environmental inputs.
Compromised epithelial permeability function represents a partial loss of compartmentalization and potentially epithelial polarization as well. These changes in epithelial function may permit increased sensitization to aeroantigens and alter cell signaling pathways that are normally regulated by segregated receptors and ligands. There are several examples of the causative role epithelial barrier dysfunction can play in disease progression outside of the airway.
10,32,33 T H 2 inflammation appears to be a potent modulator of epithelial permeability, not only in the gut but also in the skin, nasal epithelium, and 16HBE cells. 9, 11, 12 In the context of asthma, previous studies have reported decreased expression levels of certain junctional proteins, including epithelial cadherin, occluding, and zona occludens-1. 8, [34] [35] [36] Previous work has also shown that innate immune mediators such as TNF-a can influence claudin expression in airway epithelial cells. 18 The data from the present study and others implicate a crucial role for epithelial barrier dysfunction in asthma.
To date, relatively little is known about the regulation of claudins in asthma or the consequences of any changes in claudin expression to disease. Although numerous proteins make contributions to the epithelial permeability barrier, the claudin family of proteins has particular importance. Claudins form the band-like meshwork within the apical junction complex that accomplishes the sealing function between cells as well as epithelial polarization within the membrane. Claudin-18.1 is of interest because it is uniquely expressed in lung epithelia. The recent development of claudin-18 null mice has begun to advance our understanding of the function of this protein in the lung. For example, claudin-18 null mice exhibit alveolar epithelial barrier defects. In the alveolar epithelium, loss of claudin-18 results in increased paracellular permeability and altered tight junction structure between type 1 pneumocytes. 37, 38 In cultured alveolar epithelial cells the permeability-limiting function of claudin-18 is not replaced by increased expression levels of other claudin family members. 37 Interestingly, claudin-18 deficiency results in impaired alveolarization postnatally; the phenotype of claudin-18 null mice shares some similarity with animal models of bronchopulmonary dysplasia. 37 Although claudin-18 is expressed in the airways, the contribution of claudin-18 to airway barrier function has not been previously reported in detail. Ongoing development of conditional claudin-18 knock-out mice may help to separate the effects of claudin-18 deficiency on the alveolar and airway epithelium, but the data presented in this study indicate that airway epithelial permeability is higher in the absence of claudin-18.
A key finding of this study is that claudin-18 mRNA levels are reduced in the airways of subjects with asthma and that claudin-18 expression is inversely associated with T H 2 inflammation (Fig 1, A) . These data are consistent with the hypothesis that IL-13 suppresses claudin-18 expression in airway epithelial cells. The observed decrease in claudin-18 mRNA levels could be the result of a direct effect of IL-13 on claudin-18 mRNA expression or stability. Alternatively, this finding could be the result of a change in the relative abundance of particular cell populations within the epithelium that differ in claudin-18 expression levels. Claudin-18 protein levels were not examined in this study because the airway brush specimens used were too small to allow for protein-level analysis. However, there was a consistent correlation between claudin-18 mRNA and protein levels in primary airway epithelial cells and in 16HBE cells.
Atopic status is an important phenotypic feature of asthma that influences treatment decisions, but the mechanisms underpinning the association between atopy and asthma pathogenesis or progression are not entirely understood. Because environmental antigens drive T H 2 inflammation in atopic individuals, increased antigen exposure due to epithelial barrier dysfunction could potentially increase asthma severity in these patients. The findings of this study raise the possibility of an inverse association between claudin-18 levels and sensitization to inhaled environmental antigens. It should be acknowledged that the magnitude of antigen exposure is not the only determinant of serum IgE or eosinophilia, and differences among subjects with asthma could result from other factors, including T H 2 status.
To more directly test the effect of IL-13 on claudin-18 expression, primary human airway epithelial cells were cultured in the presence of IL-13. The effect of IL-13 on claudin-18 expression was also examined in vivo in IL-13-overexpressing transgenic mice. Although mouse models of asthma should be interpreted with caution, these mice are known to exhibit airway hyperresponsiveness and increased serum IgE levels following antigen exposure. 27, 28 In each of these experiments, IL-13 decreased claudin-18 levels. In contrast to studies in primary human airway epithelial cells, claudin-4 mRNA levels were significantly higher in IL-13 transgenic mice compared with wild-type mice. These data suggest that IL-13 exposure results in additional changes in airway claudin expression in mice. Barrier function was not assessed in this experiment, but previous work has demonstrated that IL-13 impairs airway epithelial barrier function. 12 To better understand the specific contribution of claudin-18 to airway epithelial barrier function, the human airway epithelial cell line 16HBE was used in loss-of-function studies. 16HBE cells form tight junctions and have been used as a model of the airway epithelial barrier. 39 In these cells, the loss of claudin-18 is sufficient to impair epithelial barrier function, including increased permeability to macromolecules. In additional experiments, airway epithelial permeability was examined in intact tracheas from claudin-18 null and wild-type mice in situ. Similarly, claudin-18 null mouse tracheas had significantly higher permeability. The mechanism by which claudin-18.1 uniquely limits epithelial permeability is not yet certain. In stomach epithelium, expression of claudin18.2 results in the formation of a distinct apical tight junction strand 40 ; however, previous studies of airway epithelial tight junction ultrastructure have not reported distinct apical strands analogous to those reported in stomach epithelium. 41, 42 Claudin-18.1 (lung) and claudin-18.2 (stomach) differ in sequence at the first of 2 extracellular domains. Although claudin-18.1 deficiency alters alveolar epithelial type 1 cell tight junction structure, 37 it is not yet clear whether claudin-18.1 deficiency results in ultrastructural changes to airway epithelial tight junctions. It remains possible that the loss of claudin-18 results in larger changes in tight junction organization or composition that compromise the permeability barrier in the airway. Although the structural relationship between claudin-18 and tight junction function requires additional investigation, the data from the present study demonstrate that claudin-18 is a requirement for normal airway epithelial permeability.
The contribution of claudin-18 deficiency to aeroantigen sensitization and airway hyperresponsiveness was examined in claudin-18 null mice using the intratracheal aspergillus sensitization model. Because claudin-18.1 expression is restricted to the lung epithelium, if the barrier defect resulting from claudin-18 deficiency augments antigen sensitization, it would follow that sensitization to antigens delivered via a route other than the airway would be similar in wild-type and clauidn-18 null mice. Therefore, mice were also sensitized with intraperitoneal aspergillus and serum IgE levels were measured. In contrast to the results of the intraairway sensitization experiments, wild-type and claudin-18 null mice had similar serum IgE levels following intraperitoneal aspergillus or OVA sensitization (Fig 4, C) . These data indicate that sensitization responses in claudin-18 null mice are not intrinsically different from those in wild-type mice, but sensitization to aeroantigens is greater in the absence of claudin-18. Although airway responsiveness and serum IgE levels differed between wild-type and knock-out mice, mucous cell hyperplasia and airway fibrosis did not significantly differ following airway aspergillus sensitization (Fig 4, D and E) . In sum, these mouse studies show that claudin-18 deficiency results in increased airway permeability and increased serum IgE levels following intraairway, but not intraperitoneal antigen exposure. Murine models of asthma have important limitations. Mouse models do not necessarily recapitulate responses observed in human subjects or tissues. Although the data from this study show a significant increase in airway permeability in human cells with clauidn-18 depletion, the sensitization responses observed in the mouse and human studies may not result from identical mechanisms.
A growing body of evidence has focused attention on airway epithelial barrier dysfunction as a central feature of asthma. The potential contributions of increased epithelial permeability and loss of epithelial polarity to asthma include heightened exposure to air space antigens and altered cell signaling due to the loss of segregation of normally polarized receptors and ligands. These abnormalities may serve to propagate allergic inflammation, increase parenchymal cell activation, and promote hyperresponsiveness. Previous studies have found that specific structural components of cell-cell junctions exhibit decreased abundance or abnormal localization in the airways of subjects with asthma. Data from this study suggest that decreased claudin-18 expression mediated by IL-13 is an additional junctional abnormality in some patients with asthma, particularly those with T H 2-high asthma. Claudin-18 appears to play a nonredundant role in the epithelial permeability barrier, potentially through effects on tight junction organization, or a more selective effect on paracellular permeability. A better understanding of the regulation of claudin-18 in disease may provide new insights for targeted therapeutics.
Key messages
d Claudin-18 is a key barrier-forming protein in the airway epithelium that is expressed at lower levels in subjects with asthma compared with healthy controls. T H 2 inflammation markers are inversely associated with claudin-18 levels in those with asthma.
d IL-13-mediated loss of claudin-18 may contribute to increased epithelial permeability, increased sensitization to aeroantigens, and airway hyperresponsiveness. 
